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While antibiotics save millions of lives globally each year, their 
indiscriminate use poses an increasingly serious threat to public 
health.[1] The emergence of antibiotic resistance is of significant 
concern, with the Centers for Disease Control and Prevention having 
estimated that in the USA alone, at least two million illnesses and 
23 000 deaths are caused by antibiotic-resistant bacteria.[2] The 
emergence of antibiotic-resistant bacteria adversely affects mortality, 
treatment costs, disease spread and duration of illness, and increases 
pressure on the choice of appropriate antibiotics as more first-line 
antibiotics are used for self-limiting conditions and bacteria become 
resistant to these.[3]
Acute bronchitis is a common reason for consultations with a 
general medical practitioner, and antibiotics are often prescribed to 
treat this self-limiting and usually viral condition.[4,5] A Cochrane 
review highlights the fact that considerable research has been done 
on the effectiveness of using antibiotics in the treatment of acute 
bronchitis.[4]
For patients presenting with acute bronchitis, the National Institute 
for Health and Care Excellence (NICE) guidelines[6] recommend that 
unless a patient is at high risk, a no-antibiotic prescribing strategy 
or a delayed antibiotic prescribing strategy should be agreed on with 
the patient. Based on the NICE guidelines, a patient is considered 
to be at high risk if he or she is systemically very unwell, has 
symptoms suggestive of serious illness/or complications, is at risk of 
complications because of pre-existing comorbidity, is a young child 
born prematurely, or is >65 years old with acute cough and two or 
more of the following criteria (or >80 years old with acute cough 
and one or more of the following criteria): (i) hospitalisation during 
the previous year; (ii) type 1 or type 2 diabetes; (iii) a history of 
congestive heart failure; and (iv) current use of oral glucocorticoids. 
For these patients, the no-antibiotic prescribing strategy and the 
delayed antibiotic prescribing strategy should not be considered.[6]
The South African (SA) Standard Treatment Guidelines and 
Essential Medicines List (SA STG/EML)[7] for the primary health-
care level recommends that antibiotics should not be given for 
uncomplicated acute bronchitis, but should be considered in patients 
infected with HIV as they are at a high risk of developing bacterial 
lower respiratory tract infections.[7] For HIV-infected patients, 
the guidelines recommend prescribing penicillin for 5 days, or 
a macrolide-like azithromycin for 3 days in penicillin-allergic 
patients. [7] For all other patients, if an antibiotic is prescribed, 
amoxicillin or tetracycline should be the first choice, while in the 
case of penicillin allergy, a tetracycline or macrolide is a good 
alternative.[8] Studies from the USA show that broad-spectrum 
macrolides are increasingly being prescribed for acute bronchitis, 
and this is not an appropriate choice considering both international 
and local recommendations.[9,10]
While national and international guidelines for treating acute 
bronchitis do not recommend the use of antibiotics,[4,6,7,11,12] more than 
50% of patients are prescribed one.[3] A study summarising multistage 
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probability surveys of ambulatory care in 
the USA reported a prescription rate of 71% 
between 1996 and 2010, from 60 - 80% 
between 1980 and 1999. [9] A study in The 
Netherlands focusing on children reported 
a prescription rate of 46% for a diagnosis 
of acute bronchitis.[13] In SA there is limited 
information on the antibiotic prescribing 
patterns of general medical practitioners for 
acute bronchitis.
Objective
The objective of this exploratory study was to 
analyse the antibiotic prescription patterns of 
SA health insurance-linked general medical 
practitioners treating patients with acute 
bronchitis, and to assess the extent to which 
the prescribing patterns are in alignment 
with evidence-informed clinical guidelines.
Methods
Approximately 8.78 million lives were 
covered by private health insurance (medical 
aid) schemes in SA in 2013. For this study, 
the 2013 claims for members of 11 health 
insurance schemes comprising 1.04 million 
lives (11.8% of the insured population) were 
analysed. Data for the study were obtained 
from the data warehouse of Towers Watson, 
an independent consulting firm providing 
consulting and actuarial services to SA health 
insurance schemes and pension funds. The 
company does not advise its clients on the 
use of the antibiotics and therefore had no 
vested interest in the outcome of the study. 
Data for the study were made available as 
part of Towers Watson’s commitment to 
support research initiatives with broader 
public health significance. The data were 
accessed in terms of and under the conditions 
set out in the consulting agreement between 
Towers Watson and their client schemes. 
The data were analysed by Towers Watson 
internally and were not made available to 
any other third party. All findings were 
presented at an aggregate level, and at no 
point was confidential scheme or member 
information disclosed.
For this study, the claims submitted to 
medical schemes for reimbursement of 
services rendered or items dispensed 
to members in the treatment of acute 
bronchitis were analysed. For each of these 
claims, the health provider submits a claim 
to the medical scheme that has at least the 
following information: (i) a unique identifier 
for the patient being treated; (ii) the date 
on which the service was rendered; (iii) a 
unique identifier for the provider providing 
the services; (iv) a code and description for 
each service rendered/item dispensed; (v) the 
ICD-10 (10th revision of the International 
Statistical Classification of Diseases and Rela­
ted Health Problems) code for the diagnosis 
of the condition being treated; (vi) a Current 
Procedural Terminology  (CPT) code for 
the procedure carried out; (vii) a National 
Pharmaceutical Product Index (NAPPI) 
code for any surgical, medical or consumable 
item dispensed; and (viii) the amount being 
claimed.
An underlying assumption of the analysis 
was that all the claims for a patient on the 
same date were related to the same ‘event’. An 
‘event’ was defined as consisting of all claims 
with the same service date from general 
practitioners and pharmacists related to the 
treatment of acute bronchitis for a particular 
patient. If the claims related to an event 
included any of the ICD-10 codes listed in 
Table 1, the event was defined as an ‘acute 
bronchitis’ event. Each acute bronchitis 
event was further categorised into one of 
three types (bacterial, viral, or unknown/
unspecified), based on the ICD-10 code 
categorisation as set out in Table 1. An event 
was considered to be positive for antibiotic 
prescription if there was a claim related to 
the event for any of the following categories 
of antibiotics: penicillins, fluoroquinolones, 
erythromycin and other macrolides, tetra-
cyclines, and chloramphenicol. Again, the 
underlying assumption was that if there 
was an antibiotic claim and a claim for the 
treatment of acute bronchitis on the same 
day, the antibiotic claim was related to the 
treatment of acute bronchitis. The study 
was limited to analyses and claims related 
to the first visit for an episode of acute 
bronchitis. Claims related to repeat visits for 
the same episode (acute bronchitis events 
for the same patient within a 7-day period) 
were excluded.
The SA STG/EML guidelines[7] recom mend 
that antibiotics should not be given for 
uncomplicated acute bronchitis, except for 
patients co-infected with HIV. The NICE 
guidelines recommend a no-antibiotic 
or delayed prescribing strategy unless 
the patient is at high risk of developing 
compli cations when he or she has acute 
bronchitis (e.g. chronically ill patients), is 
>65  years of age and has other co-morbidi-
ties, or has been confirmed to have a bacterial 
infection.[6] Given the limitations of the data 
available for this study, the extent to which 
prescribing patterns were in alignment with 
these clinical guidelines was assessed by 
analysing antibiotic prescription patterns 
by acute bronchitis type (bacterial, viral, 
unknown/unspecified), age (≤5 years, 6 - 
65  years, >65  years), gender (male, female) 
and medical status (chronic if the member 
had asthma, a cardiovascular disease, dia-
betes mellitus or HIV infection; non-chronic 
if the member did not have any of the 
stated conditions). Within these analytical 
categories, older patients (>65 years) and/or 
patients with chronic conditions (regardless 
of age) were generally considered to fall into 
the ‘high-risk’ category and were expected to 
have higher prescription rates. Chronic status 
of a member was determined on the basis 
of ongoing medicine use by the member. A 
logistic regression model was used to test 
the adjusted statistical significance of the 
association between the exploratory variables 
(bronchitis type, gender, age group and 
chronic status) and the dependent variable 
(antibiotic prescription). Sample sizes, 
percentages and odds ratios (ORs) with 95% 
confidence intervals (CIs) are reported, a 95% 
CI excluding 1 being considered statistically 
significant. The type of antibiotic prescribed 
was also assessed by type of acute bronchitis.
Table 1. Classification of acute bronchitis types by ICD-10 code
Acute bronchitis type
ICD 
code World Health Organization full description %
Bacterial (antibiotics 
may be indicated)
J20.0 Acute bronchitis due to Mycoplasma pneumoniae 0.6
J20.1 Acute bronchitis due to Haemophilus influenzae 2.3
J20.2 Acute bronchitis due to Streptococcus 2.9
Viral (antibiotics not 
indicated)
J20.3 Acute bronchitis due to Coxsackie virus 0.1
J20.4 Acute bronchitis due to parainfluenza virus 1.5
J20.5 Acute bronchitis due to respiratory syncytial virus 0.3
J20.6 Acute bronchitis due to rhinovirus 0.4
J20.7 Acute bronchitis due to echovirus 0.0
Type unknown/
unspecified
J20 Acute bronchitis 0.0
J20.8 Acute bronchitis due to other specified organisms 5.3
J20.9 Acute bronchitis; unspecified 86.6
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Research Committee, project registration 
number 15/3/24.
Results
Of the 1 043 653 lives analysed, 48.5% were 
female. By age group, 8.5% were ≤5 years, 
82.8% 6 - 65 years and 8.7% >65 years old. The 
average age was 32 years. A quarter (24.8%) of 
members had a chronic condition. Thirty-
four percent of the claims for acute bronchitis 
were from Gauteng Province, 17.2% from the 
Western Cape, 15.6% from KwaZulu-Natal, 
10.4% from the Eastern Cape, 6.4% from the 
Free State, 6.2% from Mpumalanga, 5.0% 
from the Northern Cape, 3.0% from North 
West and 2.1% from Limpopo.
There were 166 821 acute bronchitis events 
in the study population during the study 
period. Causative agents for acute bronchitis 
were determined according to the ICD-10 
codes listed in Table 1. Table 2 sets out the 
proportions of prescription rates for acute 
bronchitis by type of infection, gender, age, 
and whether a patient had a coexisting 
chronic condition or not. Antibiotics were 
prescribed in 52.9% of the acute bronchitis 
events (Table 2). However, there was some 
variation in prescription patterns across the 
various analytical categories. Compared with 
an antibiotic prescription rate of 53.6% for 
bacterial events, the prescription rate for 
viral events was significantly higher (59.2%; 
OR 1.17, 95% CI 1.08 - 1.26) and that for 
unknown/unspecified events significantly 
lower (52.7%; OR 0.95, 95% CI 0.91 - 
0.99). Prescription rates for patients with a 
chronic condition (38.2%) were significantly 
lower than those for patients without any 
of the specified chronic conditions (56.3%; 
OR 0.58; 95% CI 0.57 - 0.60). There were also 
significant differences in rates of antibiotic 
prescriptions by sex and age group. More males 
than females were prescribed antibiotics, and 
patients aged >65 years were less likely to be 
prescribed antibiotics than younger patients 
(OR 0.41, 95% CI 0.39 - 0.43).
Penicillins (27.0%), cephalosporins (5.7%) 
and other beta-lactams were the most 
commonly prescribed antibiotics (Table 3). 
Overall, almost 72% of prescriptions were 
for these antibiotics.
Discussion
Based on the study findings, health insur-
ance-linked general practitioners prescribed 
antibiotics in just over half of the acute 
bronchitis events that presented to them. 
While prescribing antibiotics for acute 
bron chitis events of a bacterial nature may 
be justified if a patient is at high risk of 
developing complications, the NICE[6] and 
SA STG/EML[7] guidelines suggest that 
anti biotics should not be prescribed for 
uncom plicated bacterial bronchitis or viral 
bronchitis, or where the causative agent is 
unknown. In this study, almost 92% of acute 
bronchitis was unknown or unspecified. Use 
of antibiotics in the viral and unknown/
unspecified events is therefore considered 
inappropriate.
With regard to age, based on the NICE 
guidelines, antibiotic use may be justified 
if the patient is >65 years of age and has a 
chronic illness.[6] Results from this study 
indicate that after adjusting for all other 
exploratory factors, patients aged >65 years 
were least likely to receive antibiotics when 
presenting for treatment of acute bronchitis. 
Similarly, with regard to medical status, 
both the NICE[6] and SA[7] guidelines 
broadly recommend that use of antibiotics 
in the treatment of acute bronchitis be 
limited to patients with chronic illnesses. 
The limitations of the data used for this 
study did not allow for the identification 
of chronically ill individuals as defined by 
Table 2. Acute bronchitis events and prescription rates
 
Events,
n (%)
Antibiotic 
prescribed, n (%)
Adjusted OR
(95% CI)
Overall 166 821 (100) 88 193 (52.9)  
Bronchitis type      
Bacterial 9 551 (5.7) 5 119 (53.6) 1
Viral 3 987 (2.4) 2 360 (59.2) 1.17 (1.08 - 1.26)*
Unknown/unspecified 153 283 (91.9) 80 714 (52.7) 0.95 (0.91 - 0.99)*
Gender      
Female 80 933 (48.5) 41 132 (50.8) 1
Male 85 888 (51.5) 47 061 (54.8) 1.15 (1.13 - 1.17)*
Age group (years)      
≤5 28 180 (16.9) 16 691 (59.2) 1.19 (1.16 - 1.22)*
6 - 65 129 268 (77.5) 69 107 (53.5) 1
>65 9 373 (5.6) 2 395 (25.6) 0.41 (0.39 - 0.43)*
Chronic      
No 135 515 (81.2) 76 240 (56.3) 1
Yes 31 306 (18.8) 11 953 (38.2) 0.58 (0.57 - 0.60)*
*p<0.01.
Table 3. Type of antibiotics prescribed by type of acute bronchitis
Acute bronchitis type
Mechanism of action Type of antibiotic
Unknown/ 
unspecified, n (%)
Bacterial,
n (%)
Viral,
n (%)
Total,
N (%)
Cell wall synthesis inhibitors Cephalosporins, penicillins, other 
beta-lactams
57 342 (71.0) 3 892 (76.0) 1 852 (78.5) 63 086 (71.5)
Protein synthesis inhibitors Macrolides, tetracyclines 8 858 (11.0) 579 (11.3) 179 (7.6) 9 616 (10.9)
DNA synthesis inhibitors Quinolones 3 869 (4.8) 224 (4.4) 140 (5.9) 4 233 (4.8)
Folic acid inhibitors Sulphonamides and combinations 1 220 (1.5) 28 (0.5) 70 (3.0) 1 318 (1.5)
Other combinations - 9 425 (11.7) 396 (7.7) 119 (5.0) 9 940 (11.3)
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both the guidelines. Instead, individuals with asthma, cardiovascular 
diseases, diabetes mellitus or HIV were used as a crude proxy. 
The sample for HIV-positive patients was too small for a separate 
analysis. After adjusting for all other exploratory factors, chronically 
ill individuals, as defined above, were significantly less likely to be 
prescribed antibiotics than non-chronically ill individuals. Data 
collected for this study did not allow us to explain the lower rates of 
antibiotic prescription for the elderly and medically compromised 
patients. It is possible that older patients and those with chronic 
illnesses were already on numerous medications, and practitioners 
were more cautious in adding to this medication intake; however, 
this theory needs to be explored further using qualitative methods.
Cephalosporins were the second most common beta-lactam 
prescribed. Neither the NICE[6] or SA[7] guidelines recommend 
cephalosporins in the treatment of acute bronchitis. Further studies 
need to be conducted to ascertain the use of cephalosporins to treat 
the condition.
Findings of this study suggest that compliance with evidence-
informed clinical guidelines for the use of antibiotics to treat acute 
bronchitis is generally poor among general medical practitioners in 
SA. Reasons for the poor compliance may be related to concerns about 
maintaining the doctor-patient relationship, patient expectations, 
and the fact that general practitioners are ‘just used to prescribing 
antibiotics’,[3] as found in other settings. There is therefore a need 
for practitioners to discuss the nature of the condition, i.e. that it is 
self-limiting but symptoms may persist for about 3 weeks, and that 
antibiotics are unlikely to be effective or substantially reduce the 
time to recovery.[14] As recommended by the NICE guidelines,[6] the 
practitioner should also consider a delayed antibiotic prescription. 
Practitioners may also consider rapid tests such as C-reactive protein 
(CRP) rapid testing, as CRP testing has been shown to potentially 
reduce prescribing of antibiotics for patients with acute respiratory 
tract infections.[15] Research shows that antibiotic prescription is 
lower when these tests are used to make a decision for prescribing 
antibiotics.[3]
Poor compliance of general practitioners with guidelines in the 
use of antibiotics for the treatment of acute bronchitis as found in 
this study raises concerns at two levels. Firstly, it raises questions 
regarding the appropriateness of antibiotic use in the treatment of 
other acute respiratory tract infections (ARTIs). Many studies have 
shown that there is little or no benefit in treating predominantly 
viral ARTIs with antibiotics.[3] Despite the evidence, the use of 
antibiotics to treat acute upper respiratory tract conditions remains 
common. Secondly, studies elsewhere have attributed increasing 
antimicrobial resistance to inappropriate use of antibiotics for self-
limiting conditions,[16] and the findings of this study raise concerns 
regarding the contribution inappropriate antibiotic use is making 
towards the growing public health concern of antibiotic resistance.
Study limitations
This study has a number of limitations. The ICD-10 codes as 
submitted by general practitioners were key to the analyses carried 
out for this study, yet there are questions around the accuracy and 
consistency of this coding. There is also some ambiguity regarding 
which ICD-10 code should be used, e.g. the Department of Health 
lists J20 as acute bronchitis and J20.0 as acute bronchitis caused by 
Mycoplasma pneumoniae.[7] Another limitation is that we assumed 
that if the acute bronchitis consultation and antibiotic provision 
were on the same day, they were directly related. Also, members of 
the scheme who opted to pay cash for treatment were not captured 
in the analyses. Furthermore, the SA STG/EML guidelines[7] give 
HIV as a chronic condition for which patients with acute bronchitis 
should be prescribed antibiotics. However, we were not able to 
determine from our sample how many patients were co-infected 
with HIV (and hence used ‘presence of a chronic condition’ as an 
exploratory factor). Despite these limitations, we believe that the 
study findings are valuable in terms of prescribing of antibiotics for 
acute bronchitis.
Conclusions
Findings of this exploratory study point to the need for further 
research and work in the use of antibiotics for acute bronchitis. 
Further research, including qualitative methods to probe reasons 
for the use of antibiotics in treating acute bronchitis, will guide local 
understanding of the extent of practitioners’ non-compliance across 
all sectors in SA. Qualitative study approaches would be valuable in 
exploring the reasons for poor compliance and identifying context-
specific approaches to improve the implementation and uptake of 
antibiotic prescribing guidelines. Without action, we may well be 
faced with a reality in the near future where we are longer able to use 
antibiotics to treat common infections.
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